Misplaced Fears in the Legislative Battle over Affordable Biotech Drugs
نویسندگان
چکیده
Much like tort reform, the debate over recently enacted legislation on biotech drugs—and particularly regulatory supplements to patent protection— has taken on a significance that dwarfs its impact on prescription drug expenditures. Under the Health Care Reform legislation, Congress enacted two major reforms: First, creation of an abbreviated Food and Drug Administration (FDA) approval process for follow-on biologics (FOBs), which are the analogues of generics for biotech drugs. Second, establishment of a twelve-year “data exclusivity” period in which clinical testing data collected by brand-name innovators can not be used by producers of FOBs to satisfy FDA testing requirements. While the abbreviated FDA approval process enjoys broad support, the data-exclusivity provision has been hotly contested, including strong opposition from the Federal Trade Commission. We argue that the debate over the duration of regulatory data exclusivity is a sideshow. Current estimates suggest that the differences in duration of the data exclusivity period that were debated, essentially between seven and twelve years, would not materially affect aggregate expenditures on prescription drugs. For this and other reasons, any potential benefit to patients that might result from a shorter period of data exclusivity are likely to be outweighed by the financial risks to the biotech industry, and particularly the negative effects on investments in research and development. * Harry Reasoner Regents Chair in Law, The University of Texas at Austin School of Law. ** Associate Professor, University of Missouri-Kansas City School of Law. This article is based in part on research conducted by Christopher M. Holman with financial support from the Biotechnology Industry Organization (BIO). The design, analysis and composition of this manuscript were independently generated by the authors, who are responsible for any errors or omissions. The views and conclusions expressed herein are those of the authors, and do not necessarily reflect the views of BIO or any of its members. 566 IDEA—The Intellectual Property Law Review 50 IDEA 565 (2010) More importantly, we believe that the focus on data exclusivity has obscured a critical flaw in the new law. Policymakers ignored the weak competition in markets for biotech drugs, which will erase much of the cost savings predicted from experience with generic versions of conventional drugs under the Hatch-Waxman Amendments to the Food, Drug and Cosmetics Act. This difference implies that the benefits of having an abbreviated FDA approval process will not be realized until policies exist that overcome the significant barriers to market entry for manufacturers of follow-on biologics—without effective competition, the pricing of biotech drugs could remain high indefinitely. We close the article by suggesting several policies to address this gap in the Health Care Reform legislation.
منابع مشابه
Patent wars: affordable medicines versus intellectual property rights.
The pharmaceutical industry is increasingly looking towards emergingmarkets, where demand for new drugs is rising rapidly alongside rates of chronic disease. But in recent years India, known as the “pharmacy of the developing world,” has led the battle for affordable drugs, using legal mechanisms to overturn patents so that its generic drug companies (which produce a fifth of the world’s generi...
متن کاملState Medicaid policy and health reform.
In July 2012, the Supreme Court upheld the constitutionality of the Patient Protection and Affordable Care Act (PPACA). The Court thus ended one phase in the political and legal battle over health reform. Yet in doing so, it opened a new front. In a notable departure from post– New Deal commerce clause jurisprudence, the Court ruled that the federal government could not require states that rece...
متن کاملWho Blinks First? Legislative Patience and Bargaining with Governors
When legislators and governors clash over the size of American state government, what strategic factors determine who wins? Efforts to address this question have traditionally relied upon setter models borrowed from the congressional literature and have predicted legislative dominance. We offer an alternative simplification of state budget negotiations that follows the “staring match” logic cap...
متن کاملEssential Drugs Production in Brazil, Russia, India, China and South Africa (BRICS): Opportunities and Challenges
The objective of this work is to elucidate various essential drugs in the Brazil, Russia, India, China and South Africa (BRICS) countries. It discusses the opportunities and challenges of the existing biotech infrastructure and the production of drugs and vaccines in member states of the BRICS. This research is based on a systematic literature review between the years 2000 and 2014 of documents...
متن کاملIntroduction to the special issue on psychotherapy, the affordable care act, and mental health parity: obstacles to implementation.
The Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 and the Affordable Care Act mandate significant insurance and patient protection reforms. Despite these safeguards, lax regulatory enforcement and lack of consumer and provider sophistication have failed to remedy ongoing insurer abuses resulting in deprivation of crucial mental health and substance abuse...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2010